The predictive utility of circulating PCSK9 levels on diabetes mellitus

• Main Authors: Jia Peng, Cheng-Gang Zhu, Jian-Jun Li
• Format: Article
• Language: English
• Published: BMC 2021-02-01
• Series: Cardiovascular Diabetology
• Subjects: Proprotein convertase subtilisin/kexin type 9; Type 2 diabetes mellitus; Risks
• Online Access: https://doi.org/10.1186/s12933-021-01226-5

Abstract Increasing data including ours have suggested that proprotein convertase subtilisin/kexin type 9 (PCSK9), a novel regulator of cholesterol metabolism, may also play an important role in the development of type 2 diabetes mellitus (T2DM) and is associated with clinical outcomes in diabetic patients. Previous studies revealed that elevated plasma PCSK9 levels had a higher incidence of new-onset T2DM. Moreover, the results of available epidemiological, preclinical, and clinical studies have indicated that plasma PCSK9 concentration is correlated with glycemic parameters and can predict the adverse cardiovascular events in diabetic patients with coronary artery disease. However, there is currently no general agreement about the association of PCSK9 with T2DM. The usefulness of the circulating PCSK9 concentration as a predictor for the risk of new-onset T2DM should be clinically prudential.